Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria

This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study investigates the efficacy, safety, and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. The study includes a screening period of up to 4 weeks, a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab, and a 16-week treatment-free period. The primary outcome is the mean change from baseline to Week 12 in the Urticaria Activity Score (UAS7). A total of 963 participants are enrolled, with 610 in the active arms and 305 in the placebo arm. The study is sponsored by Celldex Therapeutics, with a start date of July 11, 2024, and a primary completion date in October 2026.

Living with chronic spontaneous urticaria, or hives, can be incredibly challenging, especially when standard treatments like antihistamines don’t provide relief. This study is exploring a new treatment called barzolvolimab for adults who continue to experience symptoms despite taking these medications. The study involves around 915 participants who will be randomly assigned to receive either barzolvolimab or a placebo, which is a treatment with no active ingredients. Over a 24-week period, researchers will closely monitor how well barzolvolimab works compared to the placebo. The main focus will be on measuring changes in the severity of hives over time. If barzolvolimab proves effective, it could be a game-changer for many people who feel stuck with their symptoms, offering a new option for managing this frustrating condition.